SK282627B6 - Prostriedok na orálne podávanie antifungálneho činidla - Google Patents

Prostriedok na orálne podávanie antifungálneho činidla Download PDF

Info

Publication number
SK282627B6
SK282627B6 SK399-96A SK39996A SK282627B6 SK 282627 B6 SK282627 B6 SK 282627B6 SK 39996 A SK39996 A SK 39996A SK 282627 B6 SK282627 B6 SK 282627B6
Authority
SK
Slovakia
Prior art keywords
liter
cyclodextrin
itraconazole
composition
hydroxypropyl
Prior art date
Application number
SK399-96A
Other languages
English (en)
Slovak (sk)
Other versions
SK39996A3 (en
Inventor
Marc Karel Jozef Francois
Willy Maria Albert Carlo Dries
Original Assignee
Janssen Pharmaceutica N. V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N. V. filed Critical Janssen Pharmaceutica N. V.
Publication of SK39996A3 publication Critical patent/SK39996A3/sk
Publication of SK282627B6 publication Critical patent/SK282627B6/sk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
SK399-96A 1993-09-30 1994-09-22 Prostriedok na orálne podávanie antifungálneho činidla SK282627B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12950493A 1993-09-30 1993-09-30
PCT/EP1994/003169 WO1995008993A1 (en) 1993-09-30 1994-09-22 Oral formulations of an antifungal

Publications (2)

Publication Number Publication Date
SK39996A3 SK39996A3 (en) 1996-12-04
SK282627B6 true SK282627B6 (sk) 2002-10-08

Family

ID=22440301

Family Applications (1)

Application Number Title Priority Date Filing Date
SK399-96A SK282627B6 (sk) 1993-09-30 1994-09-22 Prostriedok na orálne podávanie antifungálneho činidla

Country Status (31)

Country Link
US (1) US5707975A (fi)
EP (1) EP0721337B1 (fi)
JP (1) JP3034048B2 (fi)
CN (1) CN1086579C (fi)
AP (1) AP630A (fi)
AT (1) ATE209916T1 (fi)
AU (1) AU692180B2 (fi)
CA (1) CA2170622C (fi)
CY (1) CY2272B1 (fi)
CZ (1) CZ288026B6 (fi)
DE (1) DE69429359T2 (fi)
DK (1) DK0721337T3 (fi)
ES (1) ES2169087T3 (fi)
FI (1) FI115443B (fi)
HK (1) HK1010689A1 (fi)
HU (1) HU221632B1 (fi)
IL (1) IL111093A (fi)
MY (1) MY111136A (fi)
NO (1) NO308985B1 (fi)
NZ (1) NZ273619A (fi)
OA (1) OA10276A (fi)
PH (1) PH31594A (fi)
PL (1) PL313731A1 (fi)
PT (1) PT721337E (fi)
RO (1) RO115114B1 (fi)
RU (1) RU2118899C1 (fi)
SG (1) SG48826A1 (fi)
SK (1) SK282627B6 (fi)
TW (1) TW349870B (fi)
WO (1) WO1995008993A1 (fi)
ZA (1) ZA947619B (fi)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997039761A1 (en) 1996-04-19 1997-10-30 Alpha Therapeutic Corporation A process for viral inactivation of lyophilized blood proteins
AP2000001805A0 (en) 1997-10-22 2000-06-30 Jens Ponikau Use of antifungal agents for the topical treatment of fungus-induced mucositis.
US6683100B2 (en) 1999-01-19 2004-01-27 Novartis Ag Organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
IL145140A0 (en) 1999-03-24 2002-06-30 Fmc Corp Improved aqueous solubility pharmaceutical formulations
MX339071B (es) 1999-03-31 2016-05-09 Janssen Pharmaceutica Nv Almidon pregelatinizado en una formulacion de liberacion controlada.
WO2001001955A1 (en) * 1999-07-02 2001-01-11 Janssen Pharmaceutica N.V. Nasal formulation of an antifungal
CA2291346A1 (en) 1999-11-26 2001-05-26 Bernard Charles Sherman Antifungal solutions
US6673373B2 (en) 2001-02-01 2004-01-06 Carlsbad Technology Inc. Antifungal formulation and the methods for manufacturing and using the same
US6806256B2 (en) 2001-03-05 2004-10-19 Ortho -Mcneil Pharmaceutical, Inc. Taste masked liquid pharmaceutical compositions
CA2363376A1 (en) * 2001-11-16 2003-05-16 Bernard Charles Sherman Solid pharmaceutical compositions for oral administration comprising itraconazole
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
WO2003101392A2 (en) * 2002-05-31 2003-12-11 Transform Pharmaceuticals, Inc. Novel conazole crystalline forms and related processes, pharmaceutical compositions and methods
US20030224006A1 (en) 2002-03-01 2003-12-04 Zaworotko Michael J. Multiple-component solid phases containing at least one active pharmaceutical ingredient
US7446107B2 (en) * 2002-02-15 2008-11-04 Transform Pharmaceuticals, Inc. Crystalline forms of conazoles and methods of making and using the same
US20070059356A1 (en) * 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
AU2003243699B2 (en) * 2002-06-21 2009-01-15 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
CN1255105C (zh) * 2002-12-17 2006-05-10 上海医药工业研究院 齐拉西酮及其盐的水溶性包合物及其制备方法
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
CA2440172C (en) * 2003-09-05 2011-01-11 Bernard Charles Sherman Itraconazole solution
US20050074494A1 (en) * 2003-10-06 2005-04-07 Xiu-Xiu Cheng Itraconazole immediate release formulation
US20050118265A1 (en) * 2003-11-28 2005-06-02 Anandi Krishnan Antifungal oral dosage forms and the methods for preparation
WO2005055952A2 (en) * 2003-12-08 2005-06-23 The Arizona Board Of Regents On Behalf Of The University Of Arizona Synergistic anti-cancer compositions
GR1005154B (el) 2005-02-09 2006-03-13 Verisfield (Uk) Ltd. Σταθερες φαρμακευτικες συνθεσεις ιτρακοναζολης σευδατικο περιβαλλον
US20090118721A1 (en) * 2005-07-21 2009-05-07 Eric Bornstein Near Infrared Microbial Elimination Laser System (NIMELS)
US20070082870A1 (en) * 2005-10-11 2007-04-12 Buchanan Charles M Pharmaceutical formulations of cyclodextrins and antifungal azole compounds
TWI448285B (zh) * 2006-07-13 2014-08-11 Los Angeles Biomed Res Inst 用以治療白黴菌症(mucormycosis)及其他真菌類疾病之組合物及方法
MX2009003911A (es) 2006-12-04 2009-05-28 Supernus Pharmaceuticals Inc Formulaciones de liberacion inmediata, mejoradas de topiramato.
CA2716348C (en) 2008-02-21 2017-04-04 Sequoia Pharmaceuticals, Inc. Diamide inhibitors of cytochrome p450
US20100009009A1 (en) 2008-07-10 2010-01-14 Micropure, Inc. Method and composition for prevention and treatment of oral fungal infections
US20100233101A1 (en) 2009-02-13 2010-09-16 Micropure, Inc. Composition and method for the oxidative consumption of salivary biomolecules
SG174413A1 (en) 2009-03-19 2011-10-28 Los Angeles Biomed Res Inst Vaccine compositions and methods for treatment of mucormycosis and other fungal diseases
ES2565353T3 (es) * 2010-12-16 2016-04-04 Borje S. Andersson Formulaciones farmacéuticas de azol para administración parenteral y métodos para la preparación y el uso de las mismas como tratamiento de enfermedades sensibles a los compuestos de azol
CN102670490A (zh) * 2012-05-10 2012-09-19 南京特丰药业股份有限公司 一种伊曲康唑口服溶液及其制备方法
CN103230363A (zh) * 2013-03-29 2013-08-07 湖北凤凰白云山药业有限公司 一种抗真菌的口服溶液
CA3020197A1 (en) 2017-09-01 2019-03-01 Micropure, Inc. Aliphatic anionic compounds and oxidative compounds with improved stability and efficacy for use in pharmaceutical compositions
RU2707286C1 (ru) * 2019-07-02 2019-11-26 Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" Фармацевтическая противогрибковая композиция на основе производного хлорфенилбутандиона и способ её получения
CN114191387A (zh) * 2021-12-26 2022-03-18 苏州海景医药科技有限公司 一种伏立康唑口服液的制备方法
CN114191386B (zh) * 2021-12-26 2024-03-12 苏州海景医药科技有限公司 一种波生坦口服溶液的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) * 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US4218458A (en) * 1978-06-23 1980-08-19 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-aryloxy-methyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
US4659696A (en) * 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
US4863737A (en) * 1985-05-01 1989-09-05 University Of Utah Compositions and methods of manufacture of compressed powder medicaments
US4883785A (en) * 1984-07-27 1989-11-28 Chow Wing Sun Complex of anti-fungal agent and cyclodextrin and method
GB8506792D0 (en) * 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
US4870060A (en) * 1985-03-15 1989-09-26 Janssen Pharmaceutica Derivatives of γ-cylodextrin
US4916134A (en) * 1987-03-25 1990-04-10 Janssen Pharmacuetica N.V. 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
CA1326995C (en) * 1988-01-29 1994-02-15 Kozo Kurihara Cyclosporin compositions
DE69330248T2 (de) * 1992-03-18 2002-03-21 Janssen Pharmaceutica Nv Itraconazol- und saperconazolstereoisomere

Also Published As

Publication number Publication date
FI961436A0 (fi) 1996-03-29
PH31594A (en) 1998-11-03
NO961233D0 (no) 1996-03-27
CZ288026B6 (cs) 2001-04-11
DK0721337T3 (da) 2002-03-25
NZ273619A (en) 1997-06-24
IL111093A (en) 2001-01-28
SK39996A3 (en) 1996-12-04
HU221632B1 (hu) 2002-12-28
IL111093A0 (en) 1994-11-28
DE69429359T2 (de) 2002-07-25
PL313731A1 (en) 1996-07-22
DE69429359D1 (de) 2002-01-17
TW349870B (en) 1999-01-11
SG48826A1 (en) 1998-05-18
AU692180B2 (en) 1998-06-04
RO115114B1 (ro) 1999-11-30
CZ82396A3 (en) 1996-06-12
PT721337E (pt) 2002-05-31
AP630A (en) 1998-03-10
ATE209916T1 (de) 2001-12-15
NO308985B1 (no) 2000-11-27
ZA947619B (en) 1996-03-29
CY2272B1 (en) 2003-07-04
HK1010689A1 (en) 1999-06-25
CN1136776A (zh) 1996-11-27
FI961436A (fi) 1996-03-29
CN1086579C (zh) 2002-06-26
CA2170622A1 (en) 1995-04-06
OA10276A (en) 1997-10-07
FI115443B (fi) 2005-05-13
US5707975A (en) 1998-01-13
AP9600792A0 (en) 1996-04-30
EP0721337B1 (en) 2001-12-05
AU7697994A (en) 1995-04-18
CA2170622C (en) 1999-07-27
WO1995008993A1 (en) 1995-04-06
JPH09502989A (ja) 1997-03-25
EP0721337A1 (en) 1996-07-17
HUT74378A (en) 1996-12-30
ES2169087T3 (es) 2002-07-01
MY111136A (en) 1999-08-30
RU2118899C1 (ru) 1998-09-20
NO961233L (no) 1996-03-27
JP3034048B2 (ja) 2000-04-17
HU9600804D0 (en) 1996-05-28

Similar Documents

Publication Publication Date Title
SK282627B6 (sk) Prostriedok na orálne podávanie antifungálneho činidla
US6407079B1 (en) Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
EP1267941B1 (en) Alprazolam inclusion complexes and pharmaceutical compositions thereof
DK175288B1 (da) Farmaceutiske midler indeholdende lægemidler, der er ustabile eller sparsomt oplöselige i vand, og fremgangsmåder til deres fremstilling
EP0900088B1 (en) Inclusion complexes of aryl-heterocyclic salts
EP0759741B1 (en) Mucoadhesive emulsions containing cyclodextrin
EP2402008B1 (en) Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
EP0811386B1 (en) Method of selecting a salt for making an inclusion complex
US6077871A (en) Droloxifene pharmaceutical compositions
US11141417B2 (en) Voriconazole inclusion complexes
WO2001001955A1 (en) Nasal formulation of an antifungal
US5744154A (en) Ready-to-use indomethacin-based eye lotion
ZA200207221B (en) Alprazolam inclusion complexes and pharmaceutical compositions thereof.
MXPA98009888A (en) Pharmaceutical compositions of droloxif

Legal Events

Date Code Title Description
MK4A Expiry of patent

Expiry date: 20140922